학술논문
Bevacizumab for the Treatment of Glioblastoma.
Document Type
Article
Source
Subject
*THERAPEUTIC use of monoclonal antibodies
*COMBINATION drug therapy
*CLINICAL trials
*GLIOMAS
*LONGITUDINAL method
*META-analysis
*HEALTH outcome assessment
*QUALITY of life
*VASCULAR endothelial growth factors
*TREATMENT effectiveness
*BEVACIZUMAB
*PATHOLOGIC neovascularization
*PHARMACODYNAMICS
*THERAPEUTICS
DISEASE relapse prevention
*
*
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
1179-5549
Abstract
Glioblastoma (GBM) or grade IV glioma is the most common primary brain tumor in adults. Standard treatment median overall survival (OS) is only 14-15 months and less than 10% of patients will survive 5 years after diagnosis. There is no standard treatment in recurrent GBM and OS ranges from 3 to 9 months. GBM is 1 of the most vascularized human tumors and GBM cells produce vascular endothelial growth factor (VEGF). Bevacizumab, a humanized monoclonal antibody against VEGF, has demonstrated activity in vitro and in phase II trials in relapse, as well as in 1 phase III trial as first line therapy. Bevacizumab also improves quality of life for patients suffering GBM. This paper reviews the mechanism of action of bevacizumab, its metabolism and pharmacokinetic profile. It summarizes the clinical studies in recurrent and newly diagnosed GBM, its potential side effects and complications and its place in therapy. [ABSTRACT FROM AUTHOR]